(Q38880261)

English

Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia

scientific article published on 16 April 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 September 2017

Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia (English)

1 reference

Europe PubMed Central

7 September 2017

chronic myeloid leukemia

0 references

Robert Peter Gale

4

object named as

Robert Peter Gale

1 reference

Europe PubMed Central

7 September 2017

author name string

Qian Jiang

1

1 reference

Europe PubMed Central

7 September 2017

Zheng-Chen Liu

2

1 reference

Europe PubMed Central

7 September 2017

Song-Xin Zhang

3

1 reference

Europe PubMed Central

7 September 2017

publication date

16 April 2016

1 reference

Europe PubMed Central

7 September 2017

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

7 September 2017

142

1 reference

Europe PubMed Central

7 September 2017

7

1 reference

Europe PubMed Central

7 September 2017

1539-1547

1 reference

Europe PubMed Central

7 September 2017

https://scigraph.springernature.com/pub.10.1007/s00432-016-2159-7

0 references

Patient preferences for medical decision making: who really wants to participate?

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Patients' preferences for participation in treatment decision-making at the end of life: qualitative interviews with advanced cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Factors influencing adherence to imatinib in Indian chronic myeloid leukemia patients: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Patients' preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006

1 reference

https://api.crossref.org/works/10.1007%2FS00432-016-2159-7

21 January 2018

Chronic myeloid leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/27085529

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/27085529

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-016-2159-7

1 reference

Europe PubMed Central

7 September 2017

1 reference

Europe PubMed Central

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38880261&oldid=1793407058"